Addex sends allosteric modulator into Phase II for Parkinson's
This article was originally published in Scrip
As expected, Addex Pharmaceuticals has started a Phase IIa trial to evaluate its lead internal programme, dipraglurant, in patients with Parkinson's disease levodopa-induced dyskinesia (PD-LID). The US and European study is supported in part by a grant from the Michael J. Fox Foundation for Parkinson Research. Results are due in the first half of 2012.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.